Related Experiment Video

Updated: May 30, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging

Haixun Guo1, Fabio Gallazzi, Larry A Sklar

  • 1College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA.

Bioorganic & Medicinal Chemistry Letters
|August 9, 2011
PubMed

Insights

A new imaging agent, indium-111 labeled DOTA-Ahx-(D-Lys(6)-GnRH1), effectively targets and visualizes prostate cancer in mice. This novel probe shows rapid uptake and clearance, enabling clear imaging of tumors via SPECT/CT.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical chemistry

Background:

  • Prostate cancer remains a significant health concern globally.
  • Effective diagnostic tools are crucial for early detection and treatment planning.
  • Gonadotropin-releasing hormone (GnRH) analogs show promise for targeted cancer therapies and imaging.

Purpose of the Study:

  • To assess the tumor targeting and imaging capabilities of a novel indium-111 labeled GnRH peptide, {1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Ahx-(D-Lys(6)-GnRH1)}.
  • To evaluate its potential as an imaging agent for human prostate cancer.

Main Methods:

  • The study utilized DU145 human prostate cancer-xenografted nude mice.
  • Biodistribution and tumor imaging properties of (111)In-DOTA-Ahx-(D-Lys(6)-GnRH1) were determined.
  • Single photon emission computed tomography (SPECT)/CT imaging was performed post-injection.

Main Results:

  • The radiotracer (111)In-DOTA-Ahx-(D-Lys(6)-GnRH1) demonstrated rapid tumor uptake, reaching 1.27 ± 0.40% ID/g at 0.5 hours post-injection.
  • Fast whole-body clearance was observed, primarily via the urinary system.
  • DU145 xenografted tumor lesions were clearly visualized using SPECT/CT at 0.5 hours post-injection.

Conclusions:

  • The (111)In-labeled GnRH peptide exhibits excellent tumor targeting and imaging properties for prostate cancer.
  • Its rapid clearance and clear visualization capabilities suggest potential as a novel diagnostic imaging probe.
  • This agent holds promise for enhancing the imaging of human prostate cancer.

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET